ABOS - Company ID 0001576885
Acumen Pharmaceuticals, Inc. trades as ABOS. This page tracks Acumen Pharmaceuticals, Inc. through 336 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| SCHEDULE 13G | - | 2026-04-07 |
| EFFECT | - | 2026-04-01 |
| 424B3 | - | 2026-04-01 |
The largest companies sharing Acumen Pharmaceuticals, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
In its latest fiscal year Acumen Pharmaceuticals, Inc. reported a net loss of $121.33M.